Cardiovascular risk in individuals with kidney disease

Authors

  • Selene H. Carrizales Clinica Hospital Constitucion, ISSSTE, Monterrey, Nuevo León, Mexico
  • Belen Domingo Cruz Hernandez Egresado Universidad Xochicalco, Ensenada, B.C., Mexico
  • Itzel B. C. Pineda Universidad Autónoma de Baja California, Baja California, Mexico
  • Paulina G. Valladares Universidad de Guadalajara, Guadalajara, Mexico
  • Jose R. R. Castellares Universidad Autónoma de Baja California, Baja California, Mexico
  • Mariana G. M. Velázquez Hospital General de Zona No. 32 “Dr. Mario Navarro Madrazo”, IMSS, CDMX, Mexico
  • Manuel A. V. Villegas Hospital Regional Dr. Valentín Gómez Farías, Zapopan, Mexico
  • Siomara E. L. Ruiz Universidad Autónoma de Guadalajara, Guadalajara, Mexico
  • Ulises S. Bermudez Hidra Centro de Investigación, Mexico
  • Adriana C. Aguilar Hospital General Ensenada/Universidad Autónoma de Guadalajara, Guadalajara, Mexico

DOI:

https://doi.org/10.18203/2394-6040.ijcmph20242685

Keywords:

Cardiovascular disease, Kidney disease, Epidemiology

Abstract

The worldwide prevalence of chronic kidney disease (CKD) is estimated to exceed 700 million persons, with the incidence steadily increasing due to factors such as an aging population and the growing prevalence of chronic diseases such as diabetes and hypertension. Cardiovascular disease is the primary cause of illness and mortality in persons with nephropathy. Effectively treating nephropathy and cardiovascular risk in individuals with kidney disease is a major challenge in clinical practice. Every patient requires a comprehensive assessment and tailored therapy. In order to reduce the likelihood of cardiovascular events in patients with nephropathy, it is necessary to avoid and rapidly address cardiovascular risk factors. In order to enhance the overall well-being and longevity of individuals with kidney disease, it is essential to identify and address any cardiovascular issues.

Metrics

Metrics Loading ...

References

Burnier M, Damianaki A. Hypertension as cardiovascular risk factor in chronic kidney disease. Circ Res. 2023;132(8):1050-63.

Li X, Lindholm B. Cardiovascular risk prediction in chronic kidney disease. Am J Nephrol. 2023;53(10):730-9.

Scilletta S, Di Marco M, Miano N, Filippello A, Di Mauro S, Scamporrino A, et al. Update on diabetic kidney disease (DKD): focus on non-albuminuric DKD and cardiovascular risk. Biomolecules. 2023;13(5):752.

Schuett K, Marx N, Lehrke M. The cardio-kidney patient: epidemiology, clinical characteristics and therapy. Circ Res. 2023;132(8):902-14.

Laville SM, Couturier A, Lambert O, Metzger M, Mansencal N, Jacquelinet C, et al. Urea levels and cardiovascular disease in patients with chronic kidney disease. Nephrol Dialysis Transplantat. 2023;38(1):184-92.

Kanbay M, Copur S, Siriopol D, Yildiz AB, Berkkan M, Tuttle KR, et al. The risk for chronic kidney disease in metabolically healthy obese patients: a systematic review and meta‐analysis. Eur J Clin Investig. 2023;53(1):e13878.

Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023;148(20):1606-35.

Mainieri F, La Bella S, Chiarelli F. Hyperlipidemia and cardiovascular risk in children and adolescents. Biomedicines. 2023;11(3):809.

Global Cardiovascular Risk Consortium. Global effect of modifiable risk factors on cardiovascular disease and mortality. N Engl J Med. 2023;389(14):1273-85.

Downloads

Published

2024-09-18

How to Cite

Carrizales, S. H., Egresado, B. D. C. H., Pineda, I. B. C., Valladares, P. G., Castellares, J. R. R., Velázquez, M. G. M., Villegas, M. A. V., Ruiz, S. E. L., Bermudez, U. S., & Aguilar, A. C. (2024). Cardiovascular risk in individuals with kidney disease. International Journal Of Community Medicine And Public Health, 11(10), 4085–4088. https://doi.org/10.18203/2394-6040.ijcmph20242685

Issue

Vol. 11 No. 10 (2024): October 2024

Section

Review Articles
Crossref
Scopus
Google Scholar
Europe PMC